ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 0172 • ACR Convergence 2024

    Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies

    Brandon Levian1, Charlotte Botz2, Jason Chwa2, Sophie Grove2, Vignesh Ravi2, Branden Ireifej3, daniel arkfeld4, Diana Hanna2, Jenny Hu2 and Binh Ngo2, 1Keck School of Medicine, Beverly Hills, CA, 2Keck School of Medicine, Los Angeles, 3LAGMC/Keck School of Medicine, Los Angeles, CA, 4Keck Medical Center of USC, RANCHO PALOS VERDES, CA

    Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
  • Abstract Number: 0744 • ACR Convergence 2024

    Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry

    Adrián Martín-Gutiérrez1, Juan Molina-Collada2, Marta Domínguez-Álvaro3, Rafael Benito Melero-Gonzalez4, Elisa Fernández-Fernández:5, Maite Silva-Diaz6, Jesús Alejandro Valero7, Ismael Gonzalez8, Julio Sánchez-Martín9, Javier Narvaez-García10, Itziar Calvo11, Vicente Aldasoro12, lydia Abasolo Alcazar13, ALBERTO MARIANO RUIZ ROMAN14, Javier Loricera15, Santos Castañeda16, Clara Molina Almela17, María Alcalde Villar:18, Antonio Juan-Mas19 and Ricardo Blanco-Alonso20, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4CHU Ourense, O Carballino, Spain, 5La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 6Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 7Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, 8Complejo Asistencial Universitario de Leon, León, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital Universitario de Bellvitge, Barcelona, Spain, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Universitario de Navarra, Pamplona, Spain, 13IdISSC. HCSC, Madrid, Spain, 14Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, 15Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 16Hospital Universitario de la Princesa, Madrid, Spain, 17Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 18Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 19Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 20Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
  • Abstract Number: 1106 • ACR Convergence 2024

    Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients

    Adrián Martín-Gutiérrez1, Javier Loricera2, Carmen Secada Gómez3, Clara Moriano4, Javier Narvaez-García5, Vicente Aldasoro6, Olga Maíz Alonso7, Iñigo Hernández-Rodríguez8, Paloma Vela-Casasempere9, Susana Romero Yuste10, Eugenio De Miguel11, Eva Galindez-Agirregoikoa12, Jesus C. Fernandez-López13, ivan Ferraz-Amaro14, Julio Sánchez-Martín15, José Luis Callejas16, Patricia Moya Albarado17, Cristina Campos Fernández18, Fernando Lopez-Gutierrez19, Santos Castañeda20 and Ricardo Blanco-Alonso21, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital León, LEON, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 73Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, 8Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital General Universitario Alicante, Alicante, Spain, 10Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 11Hospital Universitario La Paz, Madrid, Spain, 12BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 1311Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, 14Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 17Hospital de San Pau, Barcelona, Spain, 18Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, 19Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 20Hospital Universitario de la Princesa, Madrid, Spain, 21Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
  • Abstract Number: 1901 • ACR Convergence 2024

    Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study

    James Galloway1, Victoria Basey2, Michael Mclean2, Simon de Lusignan3 and Maya H. Buch4, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Pfizer UK, Tadworth, United Kingdom, 3Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, 4Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Risk of venous thromboembolism (VTE) is increased in people with rheumatoid arthritis (RA) when compared to the general population, but the variation of this…
  • Abstract Number: 2566 • ACR Convergence 2024

    Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study

    andriko Palmowski1, Zhivana Boydzhieva2, Paula Hoff3, Sandra Hermann3, burkhard Muche3, David Simon4, Gerhard Krönke3, Edgar Wiebe5 and FRANK HARTMUT DR. BUTTGEREIT5, 1Charité - Universittsmedizin Berlin, Berlin, Germany, 2Charité Universittsmedizin, Berlin, Germany, 3Rheumatology, Charité, Berlin, Germany, 4Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
  • Abstract Number: 0192 • ACR Convergence 2024

    Associations Between Social Determinants of Health and Acute Care Use Among Individuals with Lupus, Rheumatoid Arthritis and Osteoarthritis in the All of Us Research Program

    Candace Feldman1, Leah Santacroce1, Yomaira Silva2, Jing Cui1, Jeong Yee1, Elizabeth Karlson1 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Adverse social determinants of health (SDoH), or social risk factors like economic insecurities, inadequate health care access and neighborhood vulnerability, contribute to modifiable inequities…
  • Abstract Number: 0761 • ACR Convergence 2024

    An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

    Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

    Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
  • Abstract Number: 1124 • ACR Convergence 2024

    Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids

    Xiaodi Ruan1, Michael Williams2, Gul Karakoc1, Elizabeth McNeer1, Leena Choi1, Jonathan D. Mosley1, C. Michael Stein1 and Vivian K. Kawai1, 1Vanderbilt University Medical Center, Nashville, TN, 2VUMC, Nashville, TN

    Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…
  • Abstract Number: 2051 • ACR Convergence 2024

    Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience

    Guy Katz1, Zachary Wallace2, Grace McMahon1, Isha Jha1, Ana Fernandes1, Bohang Jiang1, Yuqing Zhang3, Hyon K. Choi4, Cory Perugino1 and John Stone5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Newton, MA, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Lexington, MA, 5Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: Rituximab (RTX) is often used to treat IgG4-related disease (IgG4-RD), but real-world data on clinical outcomes remain limited. Defining time to relapse and predictors…
  • Abstract Number: 2575 • ACR Convergence 2024

    Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?

    Paola Vidal1, Javier Narvaez-García2, Francesc-Xavier Fulladosa2, Francesca Mitjavila2, olga Capdevila2, Pol Maymó3, Judith Palacios4 and Joan Miquel Nolla2, 1Hospital Universtiario de Bellvitge, Barcelona, Spain, 2Hospital Universitario de Bellvitge, Barcelona, Spain, 3Hospital Universitario de Bellvitge., Barcelona, Spain, 4Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain

    Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
  • Abstract Number: 0207 • ACR Convergence 2024

    Investigation of Delays in Cancer Screening in RA

    Rebecca Brooks1, Cassondra Hulshizer2, Andrew C. Hanson3, Vanessa Kronzer1, John Davis1, Elena Myasoedova1 and Cynthia Crowson1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Utica, MN, 3Mayo Clinic, Rochester

    Background/Purpose: Recent studies have shown that RA patients have increased mortality due to cancer. Despite the increased mortality, few studies have investigated the completion of…
  • Abstract Number: 0802 • ACR Convergence 2024

    Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study

    Gregory McDermott1, Ritu Gill2, Suzanne Byrne3, Staci Gagne3, Xiaosong Wang4, Misti Paudel5, Emily Kowalski3, Grace Qian4, Katarina Bade3, Kevin Mueller3, Alene Saavedra3, Kathleen Vanni3, Caleb Bolden6, Tina Mahajan7, Erica Mulcaire-Jones8, Neda Kortam8, Pierre-Antoine Juge9, Tracy J Doyle10, Zachary Wallace11, Marcy Bolster6, Kevin Deane12, Dinesh Khanna8, Bryant England7 and Jeffrey Sparks13, 1Brigham and Women's Hospital, Brookline, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women’s Hospital, Boston, MA, 5Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 6Massachusetts General Hospital, Boston, MA, 7University of Nebraska Medical Center, Omaha, NE, 8University of Michigan, Ann Arbor, MI, 9Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 10Brigham and Women's Hospital, West Roxbury, MA, 11Massachusetts General Hospital, Newton, MA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
  • Abstract Number: 1151 • ACR Convergence 2024

    Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy

    Beibei Cui1, Hongjiang Liu2, Geng Yin3 and Qibing Xie4, 1Rheumatology and Immunology, Chengdu, China (People's Republic), 2West China Hospital, Sichuan University, Chengdu, China (People's Republic), 3Department of Rheumatology and Immunology, chengdu, China (People's Republic), 4Department of Rheumatology and Immunology, Chengdu, Sichuan, China

    Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…
  • Abstract Number: 2069 • ACR Convergence 2024

    Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort

    Lovely Kumari1, VISHNU KONERU2, subin Philip1, sai Kumar Dunga3, Mamatha gorijavulu4, Aishwarya Gopal5, Christina Mariaselvam6, Molly Thabah7, Vir Singh Negi8 and Chengappa Kavadichanda9, 1JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, 2JIPMER,PUDUCHERRY, PUDUCHERRY, India, 3JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, 4JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 6JIPMER, Puducherry, Puducherry, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 8AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, 9Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
  • Abstract Number: 2592 • ACR Convergence 2024

    The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood

    Jennifer Woo1 and Dale Sandler2, 1Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC, 2Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC

    Background/Purpose: Early life trauma (ELT) and neighborhood deprivation (ND)—a measure of socioeconomic position (SEP)—represent two aspects of the early life social environment that can be…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology